J. Mordenti

发表

Pharmacokinetics, tissue distribution, and expression efficiency of plasmid [33P]DNA following intravenous administration of DNA/cationic lipid complexes in mice: use of a novel radionuclide approach.

P. Godowski, T. Gadek, G. Osaka, 1996, Journal of pharmaceutical sciences.

Expression of Exposure in Negative Carcinogenicity Studies: Dose/Body Weight, Dose/Body Surface Area, or Plasma Concentrations?

J. Mordenti, A. Monro, 1995, Toxicologic pathology.

Design of Biological Equivalence Programs for Therapeutic Biotechnology Products in Clinical Development: A Perspective

J. Mordenti, James D. Green, J. Cavagnaro, 1996, Pharmaceutical Research.

Reproductive toxicity testing of therapeutic biotechnology agents.

A. Kung, J. Mordenti, J. Henck, 1996, Teratology.

Forecasting cephalosporin and monobactam antibiotic half-lives in humans from data collected in laboratory animals.

J. Mordenti, 1985, Antimicrobial Agents and Chemotherapy.

Extrapolation of Toxicological and Pharmacological Data from Animals to Humans

J. Mordenti, W. Chappell, 1991 .

Pharmacokinetic scale-up: accurate prediction of human pharmacokinetic profiles from animal data.

J. Mordenti, J Mordenti, 1985, Journal of pharmaceutical sciences.

Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation.

R. Cuthbertson, Y. Meng, A. Ryan, 1999, Toxicological sciences : an official journal of the Society of Toxicology.

A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects

T. Ouatas, D. Phung, J. Mordenti, 2017, Journal of clinical pharmacy and therapeutics.

Rational therapeutics : a clinical pharmacologic guide for the health professional

J. Mordenti, D. Brater, R. Williams, 1990 .

Inhibition of TNF by a TNF receptor immunoadhesin. Comparison to an anti-TNF monoclonal antibody.

S. Marsters, A. Ashkenazi, J. Mordenti, 1994, Journal of immunology.

Biological properties of a CD4 immunoadhesin

F. Wurm, S. Marsters, J. Groopman, 1990, Nature.

Modification of CD4 immunoadhesin with monomethoxypoly(ethylene glycol) aldehyde via reductive alkylation.

S. Shak, M. Venuti, A. Ashkenazi, 1994, Bioconjugate chemistry.

Effect of stress on the pharmacokinetics of amikacin and ticarcillin.

A. Tsuji, J. Mordenti, R. Quintiliani, 1987, Journal of pharmaceutical sciences.

Molecular and biological properties of an interleukin-1 receptor immunoadhesin.

S. Marsters, R. Pitti, A. Ashkenazi, 1994, Molecular immunology.

Phase 1 study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complex

T. L. Hodges, J. Kahn, P. Volberding, 1991, Antimicrobial Agents and Chemotherapy.

Clinical Pharmacokinetic Studies of Enzalutamide

T. Ouatas, Yoshiaki Ohtsu, J. Mordenti, 2015, Clinical Pharmacokinetics.

Transport of recombinant human CD4-immunoglobulin G across the human placenta: pharmacokinetics and safety in six mother-infant pairs in AIDS clinical trial group protocol 146

J. Mordenti, H. Minkoff, W. Shearer, 1995, Clinical and diagnostic laboratory immunology.

Designing CD4 immunoadhesins for AIDS therapy

H. Mitsuya, S. Broder, F. Wurm, 1989, Nature.

Phase I study of continuous-infusion soluble CD4 as a single agent and in combination with oral dideoxyinosine therapy in children with symptomatic human immunodeficiency virus infection.

R. Husson, A. Ammann, J. Mordenti, 1992, The Journal of pediatrics.

Prevention of HIV-1 IIIB infection in chimpanzees by CD4 immunoadhesin

J. Mordenti, D. Capon, James D. Green, 1991, Nature.

The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study.

T. L. Hodges, J. Kahn, J. Groopman, 1990, Annals of internal medicine.

Highlights of Prescribing Information

D. Wolf, J. Mordenti, W. Tremaine, 2022 .

Factor VIIa inhibitors: improved pharmacokinetic parameters.

J. Janc, Liang Liu, B. Katz, 2006, Bioorganic & medicinal chemistry letters.

Factor VIIa inhibitors: a prodrug strategy to improve oral bioavailability.

Liang Liu, J. Mordenti, J. Sukbuntherng, 2006, Bioorganic & medicinal chemistry letters.

Factor VIIa inhibitors: chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model.

J. Janc, Liang Liu, S. Hanson, 2006, Bioorganic & medicinal chemistry letters.

Small molecule inhibitors of plasma kallikrein.

B. Katz, J. Mordenti, J. Sukbuntherng, 2006, Bioorganic & medicinal chemistry letters.

Pharmacokinetics and interspecies scaling of recombinant human factor VIII.

G. Osaka, J. Mordenti, G. Meng, 1996, Toxicology and applied pharmacology.

Bactericidal action of nafcillin, vancomycin, and three cephalosporins against nafcillin-susceptible and nafcillin-resistant coagulase-negative staphylococci.

J. Mordenti, C. Lammel, G. Brooks, 1986, Diagnostic microbiology and infectious disease.

Pharmacokinetics and Tissue Distribution of Recombinant Human Transforming Growth Factor Beta1 After Topical and Intravenous Administration in Male Rats

J. Mordenti, James D. Green, T. Zioncheck, 1994, Pharmaceutical Research.

Effect of dose on pharmacokinetics and serum bactericidal activity of mezlocillin

J. Mordenti, J. Flaherty, S. Barriere, 1987, Antimicrobial Agents and Chemotherapy.

Comparisons of the Intraocular Tissue Distribution, Pharmacokinetics, and Safety of 125I-Labeled Full-Length and Fab Antibodies in Rhesus Monkeys Following Intravitreal Administration

R. Cuthbertson, Y. Meng, A. Ryan, 1999, Toxicologic pathology.

The Pharmacokinetics of Recombinant Human Relaxin in Nonpregnant Women After Intravenous, Intravaginal, and Intracervical Administration

C. Peterson, J. Mordenti, N. Chescheir, 1993, Pharmaceutical Research.

Characterization of the MN gp120 HIV-1 Vaccine: Antigen Binding to Alum

P. Berman, J. Mordenti, A. Lim, 1995, Pharmaceutical Research.

Activity of sodium ricinoleate against in vitro plaque.

J. Mordenti, J. Tanzer, R. Lindstrom, 1982, Journal of pharmaceutical sciences.

Man versus beast: pharmacokinetic scaling in mammals.

J. Mordenti, J Mordenti, 1986, Journal of pharmaceutical sciences.

Pharmacokinetic Drug Interaction Studies with Enzalutamide

T. Ouatas, Yoshiaki Ohtsu, J. Mordenti, 2015, Clinical Pharmacokinetics.

Efficacy and Concentration-Response of Murine Anti-VEGF Monoclonal Antibody in Tumor-Bearing Mice and Extrapolation to Humans

N. Ferrara, J. Mordenti, Helen Chen, 1999, Toxicologic pathology.

Vancomycin-induced neutropenia complicating bone marrow recovery in a patient with leukemia. Case report and review of the literature.

J. Mordenti, C. Ries, G. Brooks, 1986, The American journal of medicine.

Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug.

L. Presta, P. Carter, W. L. Wong, 1995, Cancer research.

Interspecies Scaling of Clearance and Volume of Distribution Data for Five Therapeutic Proteins

J. Mordenti, James D. Green, B. Ferraiolo, 1991, Pharmaceutical Research.

Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic

A. Ullrich, C. Kotts, H. Shepard, 1991, Journal of Clinical Immunology.

In vitro assessment of cytochrome P450 inhibition: strategies for increasing LC/MS-based assay throughput using a one-point IC(50) method and multiplexing high-performance liquid chromatography.

J. Mordenti, Lin Pan, Tong Lin, 2007, Journal of pharmaceutical sciences.

Estimation of Permanence Time, Exit Time, Dilution Factor, and Steady-State Volume of Distribution

A. Rescigno, J. Mordenti, 2004, Pharmaceutical Research.

The Pharmacokinetics and Absorption of Recombinant Human Relaxin in Nonpregnant Rabbits and Rhesus Monkeys After Intravenous and Intravaginal Administration

J. Mordenti, T. Nguyen, G. Fuller, 1993, Pharmaceutical Research.

Dosage regimen design for pharmaceutical studies conducted in animals.

J. Mordenti, 1986, Journal of pharmaceutical sciences.

Minimization of CYP2D6 Polymorphic Differences and Improved Bioavailability via Transdermal Administration: Latrepirdine Example

G. Ranade, B. Corrigan, J. Mordenti, 2016, Pharmaceutical Research.

The Role of Pharmacokinetics and Pharmacodynamics in the Development of Therapeutic Proteins

J. Mordenti, James D. Green, 1991 .

Effects of Formulation and Food on the Absorption of Hydrochlorothiazide and Triamterene or Amiloride from Combination Diuretic Products

L. Benet, J. Mordenti, Roger L. Williams, 1987, Pharmaceutical Research.

Engineering linear F(ab')2 fragments for efficient production in Escherichia coli and enhanced antiproliferative activity.

P. Carter, J. Ridgway, W. L. Wong, 1995, Protein Engineering.

Combination antibiotic therapy: comparison of constant infusion and intermittent bolus dosing in an experimental animal model.

J. Mordenti, R. Quintiliani, C. Nightingale, 1985, Journal of Antimicrobial Chemotherapy.

Assessment of serum bactericidal activity after administration of cefoperazone, cefotaxime, ceftizoxime, and moxalactam to healthy subjects

J. Mordenti, S. Barriere, D. C. Ozasa, 1985, Antimicrobial Agents and Chemotherapy.

A Pharmacokinetic Equation Guide for Clinicians

J. Mordenti, 1988 .

Identification of metabolites of the tryptase inhibitor CRA-9249: observation of a metabolite derived from an unexpected hydroxylation pathway.

Liang Liu, J. Mordenti, Kim Malesky, 2006, Bioorganic & medicinal chemistry letters.